chufangao/CTO huggingface dataset:
Clinical trial NCT03809650: A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Official title: A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Sponsor: Actelion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to a change in the development strategy
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-08
Primary completion date: 2020-06-29
Completion date: 2020-06-29
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04410354: Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)
Sponsor: ViralClear Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Failure to meet primary endpoint
Enrollment: 44.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-16
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Plan to share individual participant data: NO
Clinical trial NCT02133183: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
Official title: Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Other - Lapse in funding
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-02
Primary completion date: 2020-01-31
Completion date: 2023-10-31
Clinical trial NCT03712345: Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
Official title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Sponsor: InflaRx GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to COVID-19 pandemic outbreak and its impact on overall study activities. All efforts were made to ensure that participants that were enrolled and/or were still in the study will continue to receive treatment and follow-up until study completion.
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-15
Primary completion date: 2020-09-10
Completion date: 2021-05-03
Baseline population: Safety Analysis Set
Plan to share individual participant data: NO
Clinical trial NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
Official title: A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors
Sponsor: TJ Biopharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Company Development strategy adjustment
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-30
Primary completion date: 2023-02-03
Completion date: 2023-02-03
Clinical trial NCT04108962: Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Official title: Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis
Sponsor: Baylor Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Difficult to find eligible patients willing to participate.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-23
Primary completion date: 2021-09-24
Completion date: 2021-10-01
Plan to share individual participant data: NO
IPD sharing description: no subjects enrolled
Clinical trial NCT04123704: Sitravatinib in Metastatic Breast Cancer
Official title: A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer
Sponsor: Baylor Breast Care Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated by sponsor due to lack of interest
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-22
Primary completion date: 2023-01-22
Completion date: 2023-01-22
Clinical trial NCT02247128: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Official title: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Acronym: POPular-TAVI
Sponsor: St. Antonius Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1016.0 (ACTUAL)
Number of arms: 4.0
Start date: 2014-01-31
Primary completion date: 2020-03-31
Completion date: 2020-04-30
Clinical trial NCT03829046: The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Official title: The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-03
Primary completion date: 2021-11-15
Completion date: 2021-11-15
Plan to share individual participant data: UNDECIDED
IPD sharing description: This is a pilot study and all data from this trial will be used to support a bigger clinical trial to assess the role of PCSK9 inhibition in type 2 diabetes patients with cardiac microvascular dysfunction.
Clinical trial NCT02724904: Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
Official title: A Pilot Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed CNS Involvement by Lymphoma
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Drug logistics
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-31
Primary completion date: 2019-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04619706: Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19
Sponsor: Quantum Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulties recruiting new subjects
Enrollment: 53.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-14
Primary completion date: 2021-08-24
Completion date: 2021-08-24
Plan to share individual participant data: NO
Clinical trial NCT03768115: Autologous Plasma Treatment for Severe Dry Eye Patients
Official title: Use of Autologous Plasma Eyedrops Therapy for Severe Dry Eye in Singapore
Sponsor: Singapore National Eye Centre (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The inclusion criteria for plasmapheresis is too stringent to get any potential subjects.
Enrollment: 0.0 (ACTUAL)
Start date: 2018-11-01
Primary completion date: 2020-10-14
Completion date: 2020-10-14
Plan to share individual participant data: NO
Clinical trial NCT03214250: Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Official title: Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Sponsor: Parker Institute for Cancer Immunotherapy (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 129.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-07-21
Primary completion date: 2021-02-11
Completion date: 2022-02-25
Baseline population: The Phase 1b Safety Population is defined as all patients who were enrolled in Phase 1b and who received at least 1 dose of any study drug. The Phase 2 Efficacy Population is defined as all patients who were randomized in Phase 2 and who received at least 1 dose of any study drug.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04120064: Treatment of Vitamin D Deficiency With Large Bolus Cholecalciferol
Official title: Treatment of Vitamin D Deficiency With Large Bolus Cholecalciferol in the Outpatient Setting
Sponsor: Parkview Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Covid19, not able to finish recruitment
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-25
Primary completion date: 2020-12-31
Completion date: 2021-01-15
Plan to share individual participant data: NO
Clinical trial NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Official title: ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies
Acronym: ARIA
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Epizyme Inc. has revised the Tazemetostat development strategy and made the decision to terminate the hematological malignancies basket trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-12-22
Primary completion date: 2023-07-05
Completion date: 2023-07-05
Clinical trial NCT04292730: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Official title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1113.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-03-15
Primary completion date: 2020-04-29
Completion date: 2020-06-26
Baseline population: Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).~Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT03995212: Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Sponsor: Cara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment due primarily to Covid-19
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-25
Primary completion date: 2022-06-29
Completion date: 2022-06-29
Plan to share individual participant data: NO
Clinical trial NCT02983006: Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Official title: A Phase 1 Study of TRAIL-DR5 Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-31
Primary completion date: 2019-12-23
Completion date: 2021-01-01
Clinical trial NCT04443881: Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
Official title: Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection
Acronym: ANA-COVID-GEAS
Sponsor: Fundacion Miguel Servet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 179.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-08
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Plan to share individual participant data: NO
IPD sharing description: All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.
Clinical trial NCT02508636: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
Official title: Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-12-22
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Limitations and caveats: The study closed earlier than expected which resulted in a low accrual
Plan to share individual participant data: NO
Clinical trial NCT04297839: Evaluation of Regional Anticoagulation With Citrate in Extended Hemodialysis
Official title: Evaluation of the Efficacy and Safety of Regional Anticoagulation With Citrate in Extended Hemodialysis in Patients With Acute Renal Injury Admitted to an Intensive Care Unit
Sponsor: University of Sao Paulo General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: DUE TO CORONAVIRUS DISEASE, ACTIVITIES INTHE HOSPITAL ARE SUPRESSED
Enrollment: 200.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-02-12
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: UNDECIDED
IPD sharing description: The researchers have hot decided yet about this issue
Clinical trial NCT04472637: Atorvastatin Effects On Arterial Stiffness In Hemodialysis
Official title: Atorvastatin Effects On Arterial Stiffness In Hemodialysis Patients
Sponsor: Alexandria University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-01
Primary completion date: 2021-05-01
Completion date: 2021-07-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02540954: Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Official title: An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 336.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-29
Primary completion date: 2019-12-24
Completion date: 2020-06-04
Baseline population: Safety analysis set (SAF): included all participants who received any study drug
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT04750577: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
Official title: Randomised, Double-blind (Within Dose Groups), Placebo-controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Diabetic Kidney Disease
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 243.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-04-27
Primary completion date: 2022-11-30
Completion date: 2022-12-27
Baseline population: Randomised Set (RS): This patient set includes all entered and randomised patients.
Plan to share individual participant data: YES
IPD sharing description: Once the criteria in section Time Frame are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Clinical trial NCT04409288: Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Official title: Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.
Sponsor: Chinese University of Hong Kong (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Endpoint reached
Enrollment: 74.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-20
Primary completion date: 2023-10-16
Completion date: 2023-10-16
Plan to share individual participant data: NO
Clinical trial NCT04406194: Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
Official title: Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Favicovir 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions
Acronym: Favipiravir
Sponsor: Atabay Kimya Sanayi Ticaret A.S. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-14
Primary completion date: 2020-05-22
Completion date: 2020-06-19
Clinical trial NCT03257215: Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study
Official title: A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study
Acronym: D-Vex
Sponsor: Murdoch Childrens Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Recruitment very slow \& funding difficult - exacerbated by COVID-19 pandemic
Enrollment: 50.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2017-10-16
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Clinical trial NCT03876028: Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Official title: A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-11
Primary completion date: 2021-11-01
Completion date: 2021-11-01
Clinical trial NCT04775173: Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Official title: Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients With Kaposiform Hemangioendothelioma: A Trial Protocol
Sponsor: West China Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-17
Primary completion date: 2023-08-10
Completion date: 2023-08-10
Plan to share individual participant data: NO
Clinical trial NCT04795583: Corticosteroids for COVID-19
Official title: A Randomized Clinical Trial Comparing 7 Days Treatment With Corticosteroids Versus Placebo for Early COVID-19
Acronym: CORE-COVID
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Funding Issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-01
Primary completion date: 2022-04-30
Completion date: 2022-08-31